Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND IBUPROFEN vs FROVATRIPTAN SUCCINATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial extracerebral blood vessels and inhibits nociceptive trigeminal nerve transmission.
Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea
Acute treatment of migraine with or without aura in adults
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
2.5 mg orally once, may repeat after 2 hours if needed; maximum 7.5 mg in 24 hours.
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
Terminal elimination half-life is approximately 4-5 hours (range 3-6 hours). This relatively short half-life supports its use for acute migraine treatment, though it may allow for repeat dosing within 24 hours if necessary.
Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.
Primarily hepatic via CYP1A2; undergoes oxidative metabolism; some contribution from CYP2D6.
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
Primarily hepatic metabolism via CYP1A2; renal excretion accounts for ~10% of unchanged drug. Total recovery in urine and feces is ~90% over 72 hours, with ~30% in urine (mostly metabolites) and ~60% in feces.
Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).
Approximately 30% bound to plasma proteins, primarily albumin. Low protein binding suggests minimal displacement interactions.
Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).
Mean volume of distribution is approximately 2.7 L/kg, indicating extensive extravascular distribution, consistent with its CNS penetration for migraine relief.
Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.
Oral bioavailability is approximately 30% due to first-pass metabolism. No other routes are clinically approved; the drug is only available orally.
GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.
Contraindicated in severe renal impairment (Cr Cl <15 m L/min). For moderate impairment (Cr Cl 15-29 m L/min), maximum dose 2.5 mg per 24 hours. No adjustment for mild impairment.
Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.
Contraindicated in moderate to severe hepatic impairment (Child-Pugh class B or C). For mild impairment (Child-Pugh class A), no dose adjustment required.
Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.
Safety and efficacy not established in pediatric patients under 18 years of age.
Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.
No specific dose adjustment recommended based on age alone, but use with caution due to increased risk of adverse effects (e.g., cardiovascular events) and potential age-related renal impairment.
Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
Not recommended for use in patients with risk factors for coronary artery disease (CAD) unless a cardiovascular evaluation confirms absence of CAD.
Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.
Serious cardiac events including myocardial ischemia, infarction, and arrhythmias; cerebrovascular events including stroke; serotonin syndrome when coadministered with serotonergic drugs; increases in blood pressure; peripheral vascular ischemia; medication overuse headache; severe hepatic impairment.
Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.
Ischemic heart disease; history of myocardial infarction; coronary artery vasospasm; uncontrolled hypertension; hemiplegic or basilar migraine; concomitant use with ergotamines or 5-HT1 agonists; severe hepatic impairment; hypersensitivity to frovatriptan.
Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.
No specific food interactions. Avoid alcohol as it can exacerbate migraine and increase sedation risk. Grapefruit juice may increase frovatriptan levels due to CYP1A2 inhibition; limit or avoid consumption.
First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, frovatriptan caused fetal toxicity (decreased fetal weight, increased skeletal variations) at doses ≥50 mg/kg/day (approximately 100 times the MRHD). Increased risk of maternal toxicity (reduced weight gain) at high doses. Potential risk of uterine contractions and reduced uterine blood flow due to vasoconstrictive properties. Use only if potential benefit justifies risk to fetus.
Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.
Excreted in rat milk; no human data. M/P ratio unknown. Caution recommended due to potential adverse effects in nursing infants (e.g., vasoconstriction, serotonin syndrome). Decision to breastfeed or discontinue drug should consider importance of drug to mother.
No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.
No specific pharmacokinetic studies in pregnancy. Dose adjustment not established; use lowest effective dose. Caution in third trimester due to possible uterine vasoconstriction. Consider alternative therapy if frequent use needed.
Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.
Frovatriptan has a long half-life (~26 h), making it useful for prolonged migraine attacks or for menstrual migraine prophylaxis when dosed perimenstrually. Onset is slower than other triptans; not ideal for acute severe migraine requiring rapid relief. Contraindicated with MAOIs, potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin), and within 24 h of another triptan or ergotamine. Avoid in patients with hemiplegic or basilar migraine, ischemic heart disease, or uncontrolled hypertension.
Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.
Take frovatriptan at the first sign of a migraine headache, not during the aura or for prevention of typical migraines.,Swallow tablets whole with water; do not crush or chew.,If the headache returns after initial relief, a second dose may be taken after at least 2 hours, with a maximum of 3 tablets per 24 hours.,Do not use frovatriptan if you have taken another triptan or ergotamine within the last 24 hours.,Seek emergency medical attention if you experience chest pain, shortness of breath, irregular heartbeat, or signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness).,Avoid alcohol during use as it may worsen headache or increase side effects.,Inform your doctor if you are pregnant, breastfeeding, or have liver or kidney disease.,Do not drive or operate machinery until you know how frovatriptan affects you, as it may cause dizziness or drowsiness.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
"Frovatriptan, a serotonin 5-HT1B/1D receptor agonist used for acute migraine, and chlorpromazine, a first-generation antipsychotic with potent dopamine D2 receptor antagonism, can lead to additive serotonin excess when co-administered due to their combined serotonergic activity. Chlorpromazine also possesses weak serotonin reuptake inhibition properties, increasing the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Additionally, chlorpromazine may antagonize the vasoconstrictive effects of triptans via alpha-adrenergic blockade, potentially reducing migraine relief efficacy."
"Frovatriptan, a triptan used for migraine, is primarily metabolized by CYP1A2. Clotrimazole, an azole antifungal, inhibits CYP1A2, thereby reducing the clearance of frovatriptan. This can lead to increased systemic exposure to frovatriptan, potentially elevating the risk of triptan-related adverse effects such as serotonin syndrome, coronary vasospasm, and hypertension."
"Coadministration of frovatriptan, a serotonin receptor agonist metabolized primarily by CYP1A2, with simeprevir, a potent CYP3A4 inhibitor and weak CYP1A2 inducer, may result in reduced clearance of simeprevir due to competitive inhibition of CYP3A4 by frovatriptan or its metabolites. This interaction can lead to increased simeprevir plasma concentrations, elevating the risk of hepatotoxicity, photosensitivity reactions, and QT prolongation. Conversely, frovatriptan exposure is not significantly altered as its metabolism via CYP1A2 is minimally affected by simeprevir."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND IBUPROFEN vs FROVATRIPTAN SUCCINATE, answered by our medical review team.
ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. FROVATRIPTAN SUCCINATE is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial extracerebral blood vessels and inhibits nociceptive trigeminal nerve transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND IBUPROFEN and FROVATRIPTAN SUCCINATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. The standard adult dose of FROVATRIPTAN SUCCINATE is: 2.5 mg orally once, may repeat after 2 hours if needed; maximum 7.5 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND IBUPROFEN and FROVATRIPTAN SUCCINATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. FROVATRIPTAN SUCCINATE is classified as Category D/X. Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, frovatriptan caused fetal toxicity (decreased fetal weight, increased skeletal varia. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.